查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1465106

色素性視網膜炎市場：按類型、產品、最終用途分類 - 2024-2030 年全球預測

Retinitis Pigmentosa Market by Type (Autosomal Dominant Retinitis Pigmentosa, Autosomal Recessive Retinitis Pigmentosa, X-linked Retinitis Pigmentosa), Offering (Diagnosis, Treatment), End-use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年視網膜色素變性市場規模為98.5億美元，預計2024年將達106.6億美元，2030年將達180.4億美元，複合年成長率為9.02%。

色素性視網膜炎 (RP) 是一組罕見的遺傳性疾病，涉及視網膜細胞的破壞和損失，導致進行性視力喪失。這種疾病影響著全世界約四千分之一的人，是眼科和基因研究領域的一個主要問題。在意識提高、基因檢測進步和治療性介入開發的推動下，RP 治療和管理市場正在經歷適度成長。然而，新的治療方法面臨著高成本、治療選擇有限以及導致 RP 的基因突變的複雜性等挑戰。正在進行的旨在了解 RP 遺傳基礎和開發標靶治療的研究和試驗為患者提供了充滿希望的未來。此外，政府和組織加強對罕見疾病研究和資助的力度也預計將顯著提振市場。此外，治療色素性視網膜炎的持續治療和診斷進展正在創造市場成長機會。

主要市場統計
基準年[2023] 98.5億美元
預測年份 [2024] 106.6億美元
預測年份 [2030] 180.4億美元
複合年成長率（%） 9.02%

類型：由於體染色體顯性遺傳，色素性視網膜炎病例迅速增加

體染色體顯性視網膜色素變性（adRP）是一種體染色體顯性遺傳疾病。這意味著這種疾病有 50% 的機會從受影響的父母傳染給他們的孩子。患有 adRP 的人在與其病情相關的基因之一中存在足夠多的突變，導致疾病顯現。症狀通常出現在成年早期，包括夜盲症、視野狹窄和周邊視力逐漸喪失。色素性視網膜炎（arRP）是一種體染色體隱性遺傳疾病，需要遺傳兩個突變基因。這種形式的色素性視網膜炎比體染色體顯性遺傳的色素性視網膜炎不太常見，因為父母雙方具有相同基因突變的機會較低。受 arRP 影響的個體通常會出現與受 adRP 影響相似的症狀，但發病卻截然不同。患有arRP的人的父母通常是突變基因的一個拷貝的攜帶者，儘管他們本身不受影響。 X 連鎖色素性視網膜炎 (XLRP) 是一種罕見的色素性視網膜炎，透過 X 染色體遺傳。這種遺傳模式意味著它在只有一條 X 染色體的男性中更為常見。擁有兩條 X 染色體的女性不太容易感染這種疾病，而且症狀通常較輕微。 XLRP 通常始於兒童，且比其他色素性視網膜炎進展得更快。基因突變會影響視網膜感光細胞，導致進行性視力喪失。

最終用途：擴大專科診所治療和管理色素性視網膜炎的機會

居家照護為色素性視網膜炎 (RP) 患者提供舒適的家中醫療和支持性護理。這種護理的重點是透過個人化的治療計劃最大限度地提高 RP 患者的生活品質，包括醫療保健專業人員的定期監測、視覺輔助設備的指導以及日常生活活動的幫助。居家照護對於確保持續的照護和支持至關重要，特別是在晚期，患者可能會出現嚴重的視力喪失。醫院在色素性視網膜炎的診斷、治療和管理中發揮重要作用。這包括從基因檢測和諮詢到先進治療性介入的綜合服務。該醫院設有專門的眼科部門，並提供多學科的 RP 護理方法，結合最新的研究成果和治療方法。醫院治療對於需要手術和全身干預的複雜病例的初步診斷和治療至關重要。專科診所是專門治療和管理特定疾病（包括色素性視網膜炎）的機構。這些診所通常提供一般診所無法提供的專業治療，包括接觸具有深厚 RP 專業知識的眼科醫師。我們的專科診所提供先進的診斷服務、量身定做的治療計劃以及 RP 研究前沿的創新治療方法。這對於尋求專業治療並可能受益於尖端治療方法的患者至關重要。

區域洞察

在美洲，色素性視網膜炎 (RP) 正在透過大量的研發投資來解決。 FDA 已核准了多種旨在控制症狀和減緩 RP 進展的治療方法和設備。最近關於基因療法和植入式設備的專利顯示出作為未來治療方法的希望。獲得 RP 治療至關重要，因為消費者對 RP 治療的認知和支出很高，並且有保險承保。該國的全民健保系統確保治療相對容易，從而影響對 RP 管理的產品和服務的積極購買行為。在亞太地區，由於政府措施和私人投資，RP 的研究和治療方案正在迅速增加。亞太地區的消費者越來越意識到並願意投資基因檢測和新治療方法，但農村地區的可近性仍然是一個問題。政府和非政府組織積極資助 RP 研究並支持社區意識提升計劃。歐盟對 RP 採取協作方式，多個國家參與跨國研究計畫。基因治療和視網膜植入的進展值得注意，歐盟法規結構正在發揮支持作用。歐盟的消費者醫療保健支出受到涵蓋 RP 各種治療的公共衛生系統可用性的影響。在中東，人們對包括 RP 在內的遺傳疾病越來越感興趣，沙烏地阿拉伯和阿拉伯聯合大公國等國家投資於醫療基礎設施和研究。文化因素和醫療保健政策影響消費者對 RP 治療的態度，導致採用先進醫療解決方案的趨勢日益增強。非洲的情況很複雜，都市區地區在獲得永久居民待遇方面存在巨大差異。國際組織為改善醫療保健服務所做的努力以及非洲各國政府為提高對遺傳疾病的認知所做的努力至關重要。 RP 治療市場正在逐漸發展，重點是經濟實惠的解決方案。

FPNV定位矩陣

FPNV 定位矩陣對於評估視網膜色素變性市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對視網膜色素變性市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.視網膜色素變性市場的市場規模與預測是多少？

2.在視網膜色素變性市場的預測期間內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.視網膜色素變性市場的技術趨勢和法規結構是什麼？

4.視網膜色素變性市場主要供應商的市場佔有率為何？

5. 進入視網膜色素變性市場合適的形式和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球範圍內影響視網膜的罕見眼科疾病率不斷上升
      • 越來越重視基因治療和個人化醫療
    • 抑制因素
      • 色素性視網膜炎所需治療的可近性和可負擔性
    • 機會
      • 支持政府核准新開發的治療色素性視網膜炎的藥物
      • 視網膜色素變性治療和診斷的持續進展
    • 任務
      • 對疾病缺乏認知與誤診
  • 市場區隔分析
    • 類型：體染色體顯性遺傳性色素性視網膜炎導致色素性視網膜炎病例迅速增加
    • 最終用途：治療和管理色素性視網膜炎的專業診所用途的演變
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章色素性視網膜炎市場：依類型

  • 體染色體顯性遺傳性視網膜色素變性
  • 體染色體隱性遺傳色素性視網膜炎
  • X連鎖色素性視網膜炎

第7章視網膜色素變性市場：透過提供

  • 診斷
  • 治療

第 8 章色素性視網膜炎市場：依最終用途

  • 居家護理
  • 醫院
  • 專科診所

第9章美洲視網膜色素變性市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太視網膜色素變性市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲視網膜色素變性市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 市場佔有率分析（2023）
  • FPNV 定位矩陣（2023）
  • 競爭情境分析
    • jCyte 的 jCell 療法進入色素性視網膜炎的 3 期試驗
    • 楊森從 MeiraGTx 獲得開創性 XLRP 基因療法的權利，以加速視網膜疾病的進展
    • RD 基金會支持 NVAsc 視網膜治療的突破性進展
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-7A1CEDCFE674

[188 Pages Report] The Retinitis Pigmentosa Market size was estimated at USD 9.85 billion in 2023 and expected to reach USD 10.66 billion in 2024, at a CAGR 9.02% to reach USD 18.04 billion by 2030.

Retinitis Pigmentosa (RP) is a set of rare genetic conditions that involve a breakdown and loss of cells in the retina, leading to progressive vision loss. This condition affects approximately 1 in 4,000 people globally, making it a significant concern in the ophthalmological and genetic research sectors. The RP treatment and management market is witnessing gradual growth, spurred by rising awareness, advancements in genetic testing, and the development of therapeutic interventions. However, the market faces challenges such as the high cost of emerging therapies, limited availability of treatment options, and the complexity of the genetic mutations leading to RP. The ongoing research and trials aiming to understand the genetic basis of RP and to develop targeted treatments offer a promising future for patients. Moreover, growing initiatives by governments and organizations for rare disease research and funding are expected to boost the market significantly. Furthermore, ongoing treatment and diagnostics advancements to treat retinitis pigmentosa create opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 9.85 billion
Estimated Year [2024] USD 10.66 billion
Forecast Year [2030] USD 18.04 billion
CAGR (%) 9.02%

Type: Burgeoning cases of retinitis pigmentosa due to autosomal dominant retinitis pigmentosa

Autosomal dominant retinitis pigmentosa (adRP) is a genetic condition that ensues an autosomal dominant inheritance pattern. This means the disease is passed down from an affected parent to their child, with a 50% chance of inheritance. Individuals with adRP have a mutation in one of the genes associated with the condition, sufficient for the disease to manifest. Symptoms often appear in early adulthood and may include night blindness, tunnel vision, and a gradual progression to loss of peripheral vision. Autosomal recessive retinitis pigmentosa (arRP) needs the inheritance of two mutated genes for the disease to manifest in the offspring. This form of Retinitis Pigmentosa is thus less common than its autosomal dominant counterpart, given the lower probability of both parents carrying the same genetic mutations. Individuals affected by arRP typically experience similar symptoms to those with adRP, but the onset can vary widely. Parents of an individual with arRP are usually not affected themselves, but they are carriers of one copy of the mutated gene. X-linked retinitis pigmentosa (XLRP) is a rare form of Retinitis Pigmentosa transmitted through the X chromosome. This mode of inheritance means that the disease predominantly affects males with only one X chromosome. Females with two X chromosomes are less likely to be involved and often exhibit milder symptoms if they manifest the condition. XLRP is characterized by an early onset, usually in childhood, and tends to progress more rapidly than other forms of retinitis pigmentosa. The genetic mutation affects the retinal photoreceptor cells, leading to progressive vision loss.

End-use: Evolving utilization of specialty clinics for the treatment and management of retinitis pigmentosa

Homecare involves providing medical and supportive care to patients with Retinitis Pigmentosa (RP) in the comfort of their homes. This focuses on maximizing the quality of life for individuals with RP through personalized treatment plans, including regular monitoring by healthcare professionals, guidance on visual aids, and assistance in daily activities. The homecare setting is vital for ensuring continuous care and support, especially in the advanced stages of the condition, where patients may experience significant vision loss. Hospitals play a crucial role in diagnosing, treating, and managing Retinitis Pigmentosa. This involves comprehensive services that range from genetic testing and counseling to advanced therapeutic interventions. Hospitals have specialized ophthalmology departments that offer a multidisciplinary approach to RP care, incorporating the latest research findings and treatment modalities. The hospital setting is essential for the initial diagnosis and managing complex cases requiring surgical or systemic interventions. Specialty Clinics are dedicated facilities that focus on treating and managing specific disorders, including Retinitis Pigmentosa. These clinics often provide access to specialized care not available in general practice settings, including access to ophthalmologists with deep expertise in RP. Specialty clinics offer advanced diagnostic services, tailor-made treatment plans, and innovative therapies that are at the forefront of RP research. This is crucial for patients seeking expert management of their condition and for those who may benefit from cutting-edge treatment options.

Regional Insights

In the Americas, the Retinitis Pigmentosa (RP) is addressed with significant investments in research and development. The FDA has approved several treatments and devices designed to manage symptoms or slow the progression of RP. Recent patents in gene therapy and implantable devices show promise for future treatments. Consumer awareness and spending on RP treatments are high, with insurance coverage crucial in accessibility. The country's universal healthcare system ensures that treatments are relatively accessible, influencing positive purchasing behaviors toward RP management products and services. Asia-Pacific is witnessing a rapid increase in RP research and treatment options, driven by government initiatives and private investments. Asia-Pacific consumers have shown a growing awareness and willingness to invest in genetic testing and novel treatments, although accessibility issues remain in rural areas. The government and NGOs actively fund RP research and support community awareness programs. The EU has a coordinated approach to RP, with multiple countries participating in cross-border research initiatives. Advances in gene therapy and retinal implants are notable, with the EU regulatory framework playing a supportive role. Consumer healthcare spending in the EU is influenced by the availability of public healthcare systems, which cover a range of treatments for RP. There is a growing interest in genetic disorders, including RP, in the Middle East, with Saudi Arabia and the United Arab Emirates countries investing in healthcare infrastructure and research. Cultural factors and healthcare policies impact consumer attitudes toward RP treatments, with an increasing trend toward adopting advanced medical solutions. Africa presents a complex picture, with a vast discrepancy in access to RP treatments between urban and rural areas. Efforts by international organizations to improve healthcare access and initiatives by African governments to enhance genetic disorder awareness are crucial. The market for RP treatments is gradually evolving, with an emphasis on affordable solutions.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Retinitis Pigmentosa Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Retinitis Pigmentosa Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Retinitis Pigmentosa Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, Inc., Astellas Pharma Inc., Beacon Therapeutics Limited, BIOGEN INC., Clino Corporation, Coave Therapeutics SA, Editas Medicine, Inc., GENSIGHT BIOLOGICS, Genethon, Johnson & Johnson Services, Inc., MeiraGTx Holdings PLC, Mimetogen Pharmaceuticals, Nacuity Pharmaceuticals, Inc., Novartis AG, Orphagen Pharmaceuticals, Inc., Oxford Biomedica PLC, Precision BioSciences, Inc., ProQR Therapeutics N.V., Sanofi S.A., Santen Pharmaceutical Co., Ltd., Spark Therapeutics, Inc., Sun Pharmaceutical Industries Ltd., and The Wyanoke Group.

Market Segmentation & Coverage

This research report categorizes the Retinitis Pigmentosa Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Autosomal Dominant Retinitis Pigmentosa
    • Autosomal Recessive Retinitis Pigmentosa
    • X-linked Retinitis Pigmentosa
  • Offering
    • Diagnosis
    • Treatment
  • End-use
    • Homecare
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Retinitis Pigmentosa Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Retinitis Pigmentosa Market?

3. What are the technology trends and regulatory frameworks in the Retinitis Pigmentosa Market?

4. What is the market share of the leading vendors in the Retinitis Pigmentosa Market?

5. Which modes and strategic moves are suitable for entering the Retinitis Pigmentosa Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of rare eye diseases affecting retina worldwide
      • 5.1.1.2. Growing emphasis on genetic therapies and personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Accessibility and affordability of treatments required for retinitis pigmentosa
    • 5.1.3. Opportunities
      • 5.1.3.1. Supportive government approvals for newly developed drugs to treat retinitis pigmentosa
      • 5.1.3.2. Ongoing treatment and diagnostics advancements to treat retinitis pigmentosa
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness and misdiagnosis of the condition
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Burgeoning cases of retinitis pigmentosa due to autosomal dominant retinitis pigmentosa
    • 5.2.2. End-use: Evolving utilization of specialty clinics for the treatment and management of retinitis pigmentosa
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Retinitis Pigmentosa Market, by Type

  • 6.1. Introduction
  • 6.2. Autosomal Dominant Retinitis Pigmentosa
  • 6.3. Autosomal Recessive Retinitis Pigmentosa
  • 6.4. X-linked Retinitis Pigmentosa

7. Retinitis Pigmentosa Market, by Offering

  • 7.1. Introduction
  • 7.2. Diagnosis
  • 7.3. Treatment

8. Retinitis Pigmentosa Market, by End-use

  • 8.1. Introduction
  • 8.2. Homecare
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Retinitis Pigmentosa Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Retinitis Pigmentosa Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Retinitis Pigmentosa Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. jCyte's jCell Therapy Enters Phase 3 Trials for Retinitis Pigmentosa
    • 12.3.2. Janssen Acquires Rights to Pioneering XLRP Gene Therapy from MeiraGTx, Catalyzing Advancements in Retinal Diseases
    • 12.3.3. The RD Fund Backs NVasc's Breakthrough in Retinal Therapeutics
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. RETINITIS PIGMENTOSA MARKET RESEARCH PROCESS
  • FIGURE 2. RETINITIS PIGMENTOSA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. RETINITIS PIGMENTOSA MARKET DYNAMICS
  • FIGURE 7. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. RETINITIS PIGMENTOSA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. RETINITIS PIGMENTOSA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RETINITIS PIGMENTOSA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY X-LINKED RETINITIS PIGMENTOSA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY X-LINKED RETINITIS PIGMENTOSA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY DIAGNOSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY TREATMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOMECARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOMECARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL RETINITIS PIGMENTOSA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 30. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 37. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 38. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 43. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 49. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 55. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 61. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES RETINITIS PIGMENTOSA MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 83. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 89. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 95. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 101. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 107. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 119. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 131. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 137. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 143. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 157. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 163. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 169. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 175. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 181. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 187. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 193. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 205. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 211. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 217. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 223. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 229. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 247. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 253. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 265. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM RETINITIS PIGMENTOSA MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 283. RETINITIS PIGMENTOSA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 284. RETINITIS PIGMENTOSA MARKET, FPNV POSITIONING MATRIX, 2023